REG - Zotefoams PLC - Notice of Results

ZotefoamsAnnouncement

28/01/2019 07:05

RNS Number : 1914O
Zotefoams PLC
28 January 2019
 


 
Zotefoams plc
("Zotefoams" or "the Group")
 
Notice of Results
 
 
 
28 January 2019 - Zotefoams, a world leader in cellular materials technology, will announce its results for the year ending 31 December 2018 on Tuesday 19 March 2019.
 
An analyst meeting will take place at 9.30am on the day at the offices of Investec, 30 Gresham Street, London EC2V 7QN. Analysts interested in attending the presentation should please contact zach.cohen@investor-focus.co.uk.
- Ends -
 
 
 
Enquiries:
 



Zotefoams plc


+44 (0) 208 664 1600




David Stirling, Group CEO








Gary McGrath, Group CFO


















IFC Advisory


+44 (0) 203 934 6630




Graham Herring
Miles Nolan
Zach Cohen







 
 
About Zotefoams plc
Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology.  Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets.  In addition, Zotefoams owns and licenses patented MuCell® microcellular foam technology, developed specifically for extrusion applications, from a base in Massachusetts, USA to customers worldwide.
 
Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky and Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT®).  A third foam-manufacturing site, in Poland, is planned to begin operations in 2020.
 
www.zotefoams.com
 
AZOTE®, ZOTEK®, T-FIT® are registered trademarks of Zotefoams plc
MuCell® is a registered trademark of Trexel Inc.
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBAMFTMBITBFL